Karen Reckamp, MD, MS Medical Director, Clinical Research Operations
shares When Will Tumor Mutational Burden be a Standard Trials analyzing responses, not FDA-approved yet at the 2018 Oncology Summit in Huntington Beach, CA
Go to: http://www.moasc.org for more information
Advertisement